BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Botox onabotulinumtoxinA regulatory update

Allergan disclosed in its 4Q10 earnings that it submitted an sBLA to FDA for Botox onabotulinumtoxinA to treat urinary incontinence due to neurogenic detrusor...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >